Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-04620110 · 3 trials · 4 indications
Change from baseline in post-prandial area under the plasma glucose concentration time curve as determined by standardized MMTT. Linear trapezoidal method was used to compute AUC.
| Arm | Type | Description |
|---|---|---|
| PF-04620110 | EXPERIMENTAL | - |
| placebo | PLACEBO_COMPARATOR | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-04620110 | DRUG | 5 mg of PF-04620110 given once daily |
| Placebo | DRUG | Matching placebo giving for 4 weeks |
Inclusion Criteria: * Male and/or female subjects between the ages of 18 and 60 years; * Body Mass Index (BMI) of \>25.0 kg/m2 and \<40 kg/m2; * Subjects must have a historical diagnosis of T2DM in accordance with the ADA guidelines; * Subjects who have been on well-tolerated and stable doses of me...
Top 20 of 35 competitors
PF-04620110 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE) for metabolic conditions. It has been studied in overweight and obese healthy volunteers and in patients with type 2 diabetes. It is a Phase 1 candidate and is not approved for any indication.
PF-04620110 has been studied for obesity, overweight, and type 2 diabetes. Clinical trials enrolled overweight and obese otherwise healthy volunteers as well as patients with type 2 diabetes. All studies were Phase 1 and have been completed, so the drug remains investigational rather than an approved treatment.
Pfizer, Inc. (ticker PFE) is the developer of PF-04620110. The company sponsored the Phase 1 clinical program evaluating the small molecule in overweight and obese volunteers and in type 2 diabetes patients. No other developer or partnership is associated with the asset in its disclosed program.
PF-04620110 is in Phase 1 development. All three of its recorded clinical trials were Phase 1 studies, and all have been completed. The drug is investigational and has not been approved by the FDA for obesity, overweight, or type 2 diabetes.
PF-04620110 has been evaluated in three completed Phase 1 trials: NCT01298518 in type 2 diabetes patients, NCT00959426 in overweight and obese healthy volunteers, and NCT00799006 in overweight healthy volunteers. All were conducted in the United States. No trials are currently active.
The PF-04620110 program enrolled 146 participants across its three completed Phase 1 trials. NCT00959426 enrolled 71 overweight and obese healthy volunteers, NCT01298518 enrolled 48 type 2 diabetes patients, and NCT00799006 enrolled 27 overweight healthy volunteers. The studies were randomized, double-blind, and placebo-controlled.